Physician profile
Amy T Alexander
NPI 1629545512
$41,552.88
in general payments reported to CMS, 2019-2025
19 companies · $6,825 in 2025
The $6,825 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $4,680 · 2023: $19K · 2024: $9,939 · 2025: $6,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $3,695 · Travel and Lodging: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,262.50 |
| Food and Beverage | $3,695.28 |
| Travel and Lodging | $2,098.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39,473.29 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $496.55 | 2021-2024 | Uzedy, Austedo Xr |
| Alkermes, INC. | $405.23 | 2022-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $197.89 | 2022-2024 | Nuedexta, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $182.35 | 2021-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $137.10 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.74 | 2021-2024 | Caplyta |
| Axsome Therapeutics, INC. | $110.26 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $102.69 | 2021-2024 | Trintellix |
| Neos Therapeutics, LP | $52.22 | 2022 | |
| Corium, LLC | $49.16 | 2022-2023 | Azstarys |
| Lundbeck LLC | $48.35 | 2023-2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $41.77 | 2021-2022 | |
| Noven Therapeutics, LLC | $29.74 | 2024 | Secuado, Xelstrym |
| Neuronetics, INC. | $26.61 | 2023 | Neurostar Tms Therapy System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $20.90 | 2024 | |
| Supernus Pharmaceuticals, INC. | $20.65 | 2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $13.19 | 2022 | |
| Owp Pharmaceuticals, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.